jnc 8 2014 v
DESCRIPTION
HTN GUIDELINESTRANSCRIPT
![Page 1: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/1.jpg)
JNC 8 2014 V/S ESC 2013HYPERTENSION GUIDELINES- OVERVIEW
DR SUHAIL, KIMS,TRIVANDRUM
![Page 2: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/2.jpg)
SALIENT FEATURESESC JNC8• Importance of ABPM/HBPM.• White coat htn/ masked htn.• Target goal ˂ 140/90 mm hg.• Relaxation of target BP in
elderly. (>80 YRS)• No intervention in high
normal (pre htn) BP.• BB as first line drug.• Position of diuretics- first
line• Search for asymptomatic OD• Special population
stratifications
• DEFINITION = JNC7• NO GRADING OF HTN• TARGET GOAL<140/90• RELAXATION OF BP IN
ELDERLY (>60 YRS)• NO pre HTN group
• BB degraded as fourth line• Diuretic retained as first line
& FIRST• NO COMMENTS ON SPECIAL
POPULATION- INDIVIDUALISED TREATMENTS!.
![Page 3: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/3.jpg)
ESC – Class of evidences
![Page 4: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/4.jpg)
JNC8
![Page 5: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/5.jpg)
ESC- Definitions and classification of office bloodpressure levels (mmHg)
![Page 6: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/6.jpg)
JNC8
![Page 7: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/7.jpg)
Stratification of total CV risk in categories of low, moderate, high and very high risk according to SBP and DBP and prevalence of RFs, asymptomatic OD, diabetes, CKD stage or symptomatic CVD. Subjects with a high normal office but a raised out-of-office BP (masked
hypertension) have a CV risk in the hypertension range.
Authors/Task Force Members et al. Eur Heart J 2013;eurheartj.eht151
© The European Society of Hypertension (ESH) and European Society of Cardiology (ESC) 2013. All rights reserved. For permissions please email: [email protected].
ESC
![Page 8: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/8.jpg)
Comparison with JNC 7
Contd…
![Page 9: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/9.jpg)
Initiation of lifestyle changes and antihypertensive drug treatment.
Authors/Task Force Members et al. Eur Heart J 2013;eurheartj.eht151
© The European Society of Hypertension (ESH) and European Society of Cardiology (ESC) 2013. All rights reserved. For permissions please email: [email protected].
ESC
![Page 10: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/10.jpg)
JNC8
![Page 11: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/11.jpg)
![Page 12: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/12.jpg)
Initiation of antihypertensive drug treatmentESC
![Page 13: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/13.jpg)
![Page 14: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/14.jpg)
when weighing the risks and benefits of a lower BP goal for people aged 70 years or older with estimated GFR less than 60 mL/min/ 1.73m2, antihypertensive treatment should be individualized, taking into consideration factors such as frailty, comorbidities, and albuminuria
![Page 15: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/15.jpg)
Blood pressure goals in hypertensive patients
![Page 16: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/16.jpg)
Initiation of antihypertensive treatment at a DBP threshold of 90 mmHg or higher.
Treatment to a DBP goal of lower than90mm Hg reduces cerebrovascular events, heart failure, and overall mortality.
there is no benefit in treating patients to a goal of either 80mmHg or lower or 85mmHg or lower compared with90mmHg or lower.
![Page 17: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/17.jpg)
BETA BLOCKERS
• Though Cochrane meta-analysis has reported that beta-blockers may be inferior to some—but not all—other drug classes for some outcomes;
• the large meta-analysis by Law et al. has shown beta-blocker-initiated therapy to be equally as effective as the other major classes of antihypertensive agents in preventing coronary outcomes and
• highly effective in preventing CV events in patients with a recent myocardial infarction and those with heart failure.
ESC
![Page 18: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/18.jpg)
The panel did not recommend β-blockers for the initial treatment of hypertension because in one study use of β-blockers resulted in a higher rate of the primary composite outcome of cardiovascular death,myocardial infarction, or stroke compared to use of an ARB, a finding that was driven largely by an increase in stroke.
In the other studies that compared a β-blocker to the 4 recommended drug classes, the β-blocker performed similarly to the other drugs or the evidence was insufficient to make a determination
JNC8
![Page 19: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/19.jpg)
Drugs to be preferred in specific conditionsESC
![Page 20: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/20.jpg)
any of these 4 classes would be good choices as add-on agents .
this recommendation is specific for thiazide-type diuretics, which include thiazide diuretics, chlorthalidone, and indapamide; it does not include loop or potassium- sparing diuretics.
it is important that medications be dosed adequately to achieve results similar to those seen in the RCTs.
RCTs that were limited to specific non hypertensive populations, such as those with coronary artery disease or heart failure,were not reviewed for this recommendation.
Therefore, recommendation should be applied with caution to these populations.
JNC8
![Page 21: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/21.jpg)
ESC
![Page 22: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/22.jpg)
Strategies to Dose Antihypertensive Drugs
JNC8
![Page 23: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/23.jpg)
JNC8
![Page 24: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/24.jpg)
SPECIAL POPULATIONS
![Page 25: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/25.jpg)
any of these 4 classes would be good choices as add-on agents .
this recommendation is specific for thiazide-type diuretics, which include thiazide diuretics, chlorthalidone, and indapamide; it does not include loop or potassium- sparing diuretics.
it is important that medications be dosed adequately to achieve results similar to those seen in the RCTs.
RCTs that were limited to specific non hypertensive populations, such as those with coronary artery disease or heart failure,were not reviewed for this recommendation.
Therefore, recommendation should be applied with caution to these populations.
![Page 26: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/26.jpg)
Treatment strategies in white-coat and maskedhypertension
![Page 27: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/27.jpg)
Antihypertensive treatment strategies in the elderly
![Page 28: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/28.jpg)
Treatment strategies in hypertensive women
![Page 29: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/29.jpg)
Treatment strategies in patients with diabetes
![Page 30: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/30.jpg)
JNC & ESC• NO PRE HTN• LIBERAL IN ELDERLY
ACEI, ARB & CCB- FIRST LINE
![Page 31: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/31.jpg)
Treatment strategies in hypertensive patients withmetabolic syndrome
![Page 32: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/32.jpg)
Therapeutic strategies in hypertensive patients withnephropathy
![Page 33: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/33.jpg)
Therapeutic strategies in hypertensive patients withcerebrovascular disease
![Page 34: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/34.jpg)
Therapeutic strategies in hypertensive patients withheart disease
![Page 35: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/35.jpg)
Therapeutic strategies in hypertensive patients withatherosclerosis, arteriosclerosis, and peripheral artery
disease
![Page 36: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/36.jpg)
Therapeutic strategies in patients with resistanthypertension
![Page 37: Jnc 8 2014 v](https://reader033.vdocuments.mx/reader033/viewer/2022061400/554b3fc9b4c905ff268b4b23/html5/thumbnails/37.jpg)
Treatment of risk factors associated with hypertension